Australia Vaccine Market

Australia Vaccine Market Overview:

The Australia vaccine market size reached USD 1,196.0 Million in 2024. Looking forward, IMARC Group expects the market to reach USD 2,629.9 Million by ​2033​, exhibiting a growth rate (CAGR) of 9.15% during 2025-2033. The growing public health awareness, rising infectious disease prevalence, national immunization programs, growing elderly population, escalating preventive healthcare focus, technological innovation, expanding cold chain logistics, and public-private research and development (R&D) collaborations are some of the factors bolstering the market growth.

Australia Vaccine Market Trends:

Rising Prevalence of Infectious Diseases

The increasing incidence of infectious diseases such as influenza, meningococcal disease, and whooping cough, and growing cases of respiratory diseases continues to drive the Australia vaccine market growth. In 2024, Australia experienced its highest recorded influenza season, with over 351,641 laboratory-confirmed cases, surpassing the previous record of 313,454 cases in 2019. Moreover, increasing pathogens and zoonotic diseases has compelled the government and healthcare providers to focus on immunization, which is fostering the market growth. In line with this, the pharmaceutical and biotechnology industries are actively investing in new vaccine in order to meet the evolving nature of disease, which is another growth-inducing factor. Furthermore, the mounting disease burden has surged routine immunization campaigns and escalated the need for advanced, broad-spectrum, and speed-of-response vaccines targeting local as well as global health issues, which is accelerating the market growth.

Government Support Through National Immunization Programs

Australia's National Immunization Program (NIP) plays a key role in propelling the vaccine market by providing free access to vital vaccines to deserving recipients. The policy framework yields high vaccine coverage rates, reduces cases of vaccine-preventable diseases, and stabilizes routine immunization demand. The NIP includes diphtheria, tetanus, pertussis, polio, measles, mumps, rubella, and influenza vaccines, among others, and is periodically updated to include new indications and age groups based on clinical evidence and public health priorities. The funding and centralized procurement model streamlines supply chains and fosters economies of scale, which incentivizes both local and foreign vaccine manufacturers to be part of the market. Apart from this, surging public awareness campaigns and availability of online health programs are boosting the Australia vaccine market share.

Growing Awareness of Preventive Healthcare

A shift in public health precedence from curative care to preventive intervention has strongly influenced vaccine uptake across Australia. Growing health literacy, augmented by governmental campaigns and online access to information, has enhanced community understanding of the role of vaccines in disease prevention and long-term health outcomes, which is fueling the market growth. For instance, the Preventive and Public Health Research Initiative made a commitment to invest around USD 545.1 million in next ten years. This program supports research on risk factors for chronic and complex disease to strengthen preventive healthcare interventions. Consumers are becoming more proactive in seeking immunizations against childhood illnesses, travel risks, seasonal infections, and age-related illnesses ,such as shingles and pneumococcal disease. Furthermore, the growing demand for adult and travel vaccines is creating new growth opportunities for manufacturers and distributors, which is creating a positive Australia vaccine market outlook.

Australia Vaccine Market Segmentation:

IMARC Group provides an analysis of the key trends in each segment of the market, along with forecasts at the region level for 2025-2033. Our report has categorized the market based on technology, patient type, indication, route of administration, product type, treatment type, distribution channel, and end user.

Technology Insights:

• Conjugate Vaccines
• Inactivated and Subunit Vaccines
• Live Attenuated Vaccines
• Recombinant Vaccines
• Toxoid Vaccines
• Others 

The report has provided a detailed breakup and analysis of the market based on the technology. This includes conjugate vaccines, inactivated and subunit vaccines, live attenuated vaccines, recombinant vaccines, toxoid vaccines, and others.

Patient Type Insights:

• Paediatric
• Adult

A detailed breakup and analysis of the market based on the patient type have also been provided in the report. This includes paediatric and adult.

Indication Insights:

• Bacterial Diseases
  • Meningococcal Disease
  • Pneumococcal Disease
  • Diphtheria/Tetanus/Pertussis (DPT)
  • Tuberculosis
  • Haemophilus Influenzae (Hib)
  • Typhoid
  • Others
• Viral Diseases
  • Hepatitis
  • Influenza
  • Human Papillomavirus (HPV)
  • Measles/Mumps/Rubella (MMR)
  • Rotavirus
  • Herpes Zoster
  • Varicella
  • Japanese Encephalitis
  • Rubella
  • Polio
  • Rabies
  • Dengue
  • Others

The report has provided a detailed breakup and analysis of the market based on the indication. This includes bacterial diseases (meningococcal disease, pneumococcal disease, diphtheria/tetanus/pertussis (DPT), tuberculosis, haemophilus influenzae (Hib), typhoid, and others) and viral diseases (hepatitis, influenza, human papillomavirus (HPV), measles/mumps/rubella (MMR), rotavirus, herpes zoster, varicella, japanese encephalitis, rubella, polio, rabies, dengue, and others).

Route of Administration Insights:

• Intramuscular and Subcutaneous Administration
• Oral Administration
• Others

A detailed breakup and analysis of the market based on the route of administration have also been provided in the report. This includes intramuscular and subcutaneous administration, oral administration, and others.

Product Type Insights:

• Multivalent Vaccine
• Monovalent Vaccine 

The report has provided a detailed breakup and analysis of the market based on the product type. This includes multivalent vaccine and monovalent vaccine.

Treatment Type Insights:

• Preventive Vaccine
• Therapeutic Vaccine

A detailed breakup and analysis of the market based on the treatment type have also been provided in the report. This includes preventive vaccine and therapeutic vaccine.

Distribution Channel Insights:

• Hospital Pharmacies
• Retail Pharmacies
• Institutional Sales
• Others 

The report has provided a detailed breakup and analysis of the market based on the distribution channel. This includes hospital pharmacies, retail pharmacies, institutional sales, and others.

End User Insights:

• Hospitals
• Clinics
• Vaccination Centers
• Academic and Research Institutes
• Others

A detailed breakup and analysis of the market based on the end user have also been provided in the report. This includes hospitals, clinics, vaccination centers, academic and research institutes, and others.

Regional Insights:

• Australia Capital Territory & New South Wales
• Victoria & Tasmania
• Queensland
• Northern Territory & Southern Australia
• Western Australia

The report has also provided a comprehensive analysis of all the major regional markets, which include Australia Capital Territory & New South Wales, Victoria & Tasmania, Queensland, Northern Territory & Southern Australia, and Western Australia.

Competitive Landscape:

The market research report has also provided a comprehensive analysis of the competitive landscape. Competitive analysis such as market structure, key player positioning, top winning strategies, competitive dashboard, and company evaluation quadrant has been covered in the report. Also, detailed profiles of all major companies have been provided.

Australia Vaccine Market News:

• In 2025, the Australian government opened Moderna's mRNA vaccine manufacturing facility in Melbourne, established under a USD 2 billion agreement initiated during the Morrison administration.
• In 2023, CSL Seqirus celebrated a construction milestone for its cell-based influenza vaccine manufacturing facility in Melbourne. The facility is set to produce seasonal and pandemic influenza vaccines using innovative cell-based technology, with production expected to commence in 2026. This development aims to bolster Australia's sovereign vaccine manufacturing capabilities and ensure a reliable supply of influenza vaccines

Australia Vaccine Market Report Coverage:

Key Questions Answered in This Report:

• How has the Australia vaccine market performed so far and how will it perform in the coming years?
• What is the breakup of the Australia vaccine market on the basis of technology?
• What is the breakup of the Australia vaccine market on the basis of patient type?
• What is the breakup of the Australia vaccine market on the basis of indication?
• What is the breakup of the Australia vaccine market on the basis of route of administration?
• What is the breakup of the Australia vaccine market on the basis of product type?
• What is the breakup of the Australia vaccine market on the basis of treatment type?
• What is the breakup of the Australia vaccine market on the basis of distribution channel?
• What is the breakup of the Australia vaccine market on the basis of end user?
• What is the breakup of the Australia vaccine market on the basis of region?
• What are the various stages in the value chain of the Australia vaccine market? 
• What are the key driving factors and challenges in the Australia vaccine?
• What is the structure of the Australia vaccine market and who are the key players?
• What is the degree of competition in the Australia vaccine market? 

Key Benefits for Stakeholders:

• IMARC’s industry report offers a comprehensive quantitative analysis of various market segments, historical and current market trends, market forecasts, and dynamics of the Australia vaccine market from 2019-2033.
• The research report provides the latest information on the market drivers, challenges, and opportunities in the Australia vaccine market.
• Porter's five forces analysis assist stakeholders in assessing the impact of new entrants, competitive rivalry, supplier power, buyer power, and the threat of substitution. It helps stakeholders to analyze the level of competition within the Australia vaccine industry and its attractiveness.
• Competitive landscape allows stakeholders to understand their competitive environment and provides an insight into the current positions of key players in the market.